TerminatedNCT05603104
Earlier medication changes after a first treatment fails for schizophrenia, depression, or bipolarity
About this title
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Read the official source — NCT05603104Medication studyAges 18–70Israel
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- Ramat GanSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 27, 2025
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1,254
- Sponsor
- Dr. Inge Winter
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Israel
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05603104
- Official title
Show the full official title
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ramat Gan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Dr. Inge Winter.
Does this study involve medication?
Yes. The study involves medication, including Clozapine, Esketamine Nasal Product, Escitalopram, Sertraline, Venlafaxine, lithium, Valproate acid, Quetiapine, Second-line Antidepressants, Second-line Antipsychotics, Ketamine Hydrochloride, Esketamine hydrochloride and Bupropion.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
Monthly cariprazine injections for schizophrenia, bipolarity, or depression
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolarity type I, and Major Depressive Disorder
